Soleno Therapeutics reported stronger-than-expected sales growth for Vykat XR, the first FDA-approved treatment for hyperphagia in Prader-Willi syndrome, with net revenues between $31 million and $33 million for Q2 2025. Despite favorable demand and reimbursement, the company’s shares declined amid a $200 million stock offering aimed at supporting the drug’s launch. Meanwhile, Antag Therapeutics prepares for an imminent Phase 1 readout of its GIP blockade agent for obesity, exploring an antagonistic approach contrary to some current therapies.